key: cord-0076096-ympx3h5d
authors: Turco, F.; Smith, M.; Omlin, A.; Gillessen, S.
title: Letter to the Editor - Reply: Manuscript Number: EURUROL-D-22-00214 “Brief communication: What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021“
date: 2022-03-28
journal: Eur Urol
DOI: 10.1016/j.eururo.2022.03.029
sha: 94c2c82c40b07ae30040d5fb934f014b1653102f
doc_id: 76096
cord_uid: ympx3h5d

nan

The APCCC panel reached a strong consensus (agreement of 97% of panelists) that COVID19 vaccination should be recommended for all patients with advanced prostate cancer. Accordingly, we agree with the suggestion that COVID19 vaccination should be recommended also to the subset of patients with advanced prostate cancer who enroll in clinical trials. But we strongly believe that the recommendation for vaccination should not be limited to this subgroup of patients.

In the ARASENS trial, the risk of death was 32.5% lower in the darolutamide group than in the placebo group (hazard ratio, 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001)₂. The primary analysis for overall survival prespecified and occurred after a total of 533 deaths were observed. The six deaths attributed to COVID19 represent less than 1.1% of all deaths and had no meaningful impact on the study results.

What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Manuscript Click here to view linked References Consensus Conference 2021